Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C.

Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8.

2.

KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.

Tessitore A, Bruera G, Mastroiaco V, Cannita K, Cortellini A, Cocciolone V, Dal Mas A, Calvisi G, Zazzeroni F, Ficorella C, Ricevuto E, Alesse E.

Hum Pathol. 2018 Apr;74:178-182. doi: 10.1016/j.humpath.2018.01.021. Epub 2018 Jan 31.

PMID:
29409955
3.

GADD45β Loss Ablates Innate Immunosuppression in Cancer.

Verzella D, Bennett J, Fischietti M, Thotakura AK, Recordati C, Pasqualini F, Capece D, Vecchiotti D, D'Andrea D, Di Francesco B, De Maglie M, Begalli F, Tornatore L, Papa S, Lawrence T, Forbes SJ, Sica A, Alesse E, Zazzeroni F, Franzoso G.

Cancer Res. 2018 Mar 1;78(5):1275-1292. doi: 10.1158/0008-5472.CAN-17-1833. Epub 2017 Dec 26.

4.

Next-generation sequencing: recent applications to the analysis of colorectal cancer.

Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, Capalbo C, Alesse E, Tessitore A.

J Transl Med. 2017 Dec 8;15(1):246. doi: 10.1186/s12967-017-1353-y. Review.

5.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Cocciolone V, Cannita K, Calandrella ML, Ricevuto E, Baldi PL, Sidoni T, Irelli A, Paradisi S, Pizzorno L, Resta V, Bafile A, Alesse E, Tessitore A, Ficorella C.

Oncotarget. 2017 Jun 16;8(42):72031-72043. doi: 10.18632/oncotarget.18526. eCollection 2017 Sep 22.

6.

Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model.

Tessitore A, Mastroiaco V, Vetuschi A, Sferra R, Pompili S, Cicciarelli G, Barnabei R, Capece D, Zazzeroni F, Capalbo C, Alesse E.

Oncotarget. 2017 Jun 21;8(32):53482-53494. doi: 10.18632/oncotarget.18585. eCollection 2017 Aug 8.

7.

Cancer secretome and inflammation: The bright and the dark sides of NF-κB.

Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzeroni F.

Semin Cell Dev Biol. 2018 Jun;78:51-61. doi: 10.1016/j.semcdb.2017.08.004. Epub 2017 Aug 2. Review.

8.

Effects of reduced natural background radiation on Drosophila melanogaster growth and development as revealed by the FLYINGLOW program.

Morciano P, Iorio R, Iovino D, Cipressa F, Esposito G, Porrazzo A, Satta L, Alesse E, Tabocchini MA, Cenci G.

J Cell Physiol. 2018 Jan;233(1):23-29. doi: 10.1002/jcp.25889. Epub 2017 Jun 5.

PMID:
28262946
9.

New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.

Cannita K, Paradisi S, Cocciolone V, Bafile A, Rinaldi L, Irelli A, Lanfiuti Baldi P, Zugaro L, Manetta R, Alesse E, Ricevuto E, Ficorella C.

Cancer Med. 2016 Sep;5(9):2232-9. doi: 10.1002/cam4.803. Epub 2016 Jul 15.

10.

Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis.

Cipriani P, Di Benedetto P, Ruscitti P, Liakouli V, Berardicurti O, Carubbi F, Ciccia F, Guggino G, Zazzeroni F, Alesse E, Triolo G, Giacomelli R.

J Rheumatol. 2016 Jul;43(7):1340-9. doi: 10.3899/jrheum.150996. Epub 2016 Jun 1.

PMID:
27252423
11.

MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.

Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E.

BMC Cancer. 2016 Jan 5;16:3. doi: 10.1186/s12885-015-2007-1.

12.

Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model.

Del Vecchio F, Gallo F, Di Marco A, Mastroiaco V, Caianiello P, Zazzeroni F, Alesse E, Tessitore A.

BMC Bioinformatics. 2015 Dec 10;16:408. doi: 10.1186/s12859-015-0836-1.

13.

Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.

Cipriani P, Di Benedetto P, Ruscitti P, Verzella D, Fischietti M, Zazzeroni F, Liakouli V, Carubbi F, Berardicurti O, Alesse E, Giacomelli R.

Arthritis Res Ther. 2015 Sep 10;17:247. doi: 10.1186/s13075-015-0754-7.

14.

Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?

Verzella D, Fischietti M, Capece D, Vecchiotti D, Del Vecchio F, Cicciarelli G, Mastroiaco V, Tessitore A, Alesse E, Zazzeroni F.

Curr Drug Targets. 2016;17(3):311-20.

PMID:
26343112
15.

Therapeutic Use of MicroRNAs in Cancer.

Tessitore A, Cicciarelli G, Mastroiaco V, Vecchio FD, Capece D, Verzella D, Fischietti M, Vecchiotti D, Zazzeroni F, Alesse E.

Anticancer Agents Med Chem. 2016;16(1):7-19. Review.

PMID:
26299662
16.

The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.

Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzeroni F, Liakouli V, Pantano I, Berardicurti O, Carubbi F, Pecetti G, Turricchia S, Alesse E, Iglarz M, Giacomelli R.

J Rheumatol. 2015 Oct;42(10):1808-16. doi: 10.3899/jrheum.150088. Epub 2015 Aug 15.

PMID:
26276964
17.

The role of IL-1β in the bone loss during rheumatic diseases.

Ruscitti P, Cipriani P, Carubbi F, Liakouli V, Zazzeroni F, Di Benedetto P, Berardicurti O, Alesse E, Giacomelli R.

Mediators Inflamm. 2015;2015:782382. doi: 10.1155/2015/782382. Epub 2015 Apr 12. Review.

18.

The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E.

Crit Rev Oncol Hematol. 2015 Mar;93(3):190-202. doi: 10.1016/j.critrevonc.2014.10.004. Epub 2014 Oct 16. Review.

PMID:
25459669
19.

Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis.

Cipriani P, Di Benedetto P, Capece D, Zazzeroni F, Liakouli V, Ruscitti P, Pantano I, Berardicurti O, Carubbi F, Alesse E, Giacomelli R.

Fibrogenesis Tissue Repair. 2014 Sep 15;7:13. doi: 10.1186/1755-1536-7-13. eCollection 2014.

20.

Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Rucci N, Sanità P, Delle Monache S, Alesse E, Angelucci A.

World J Clin Oncol. 2014 Aug 10;5(3):335-47. doi: 10.5306/wjco.v5.i3.335. Review.

21.

KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.

Zazzeroni F, Nicosia D, Tessitore A, Gallo R, Verzella D, Fischietti M, Vecchiotti D, Ventura L, Capece D, Gulino A, Alesse E.

Biomed Res Int. 2014;2014:380398. doi: 10.1155/2014/380398. Epub 2014 Jun 19.

22.

MicroRNAs in the DNA Damage/Repair Network and Cancer.

Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Vecchiotti D, Capece D, Zazzeroni F, Alesse E.

Int J Genomics. 2014;2014:820248. doi: 10.1155/2014/820248. Epub 2014 Jan 30. Review.

23.

Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.

Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A.

Endocr Relat Cancer. 2013 Sep 16;20(5):753-66. doi: 10.1530/ERC-12-0322. Print 2013 Oct.

PMID:
23940012
24.

A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.

Capece D, Zazzeroni F, Mancarelli MM, Verzella D, Fischietti M, Di Tommaso A, Maccarone R, Plebani S, Di Ianni M, Gulino A, Alesse E.

PLoS One. 2013 Jul 9;8(7):e68080. doi: 10.1371/journal.pone.0068080. Print 2013.

25.

Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers.

Tessitore A, Zazzeroni F, Alesse E.

Expert Rev Proteomics. 2013 Jun;10(3):223-6. doi: 10.1586/epr.13.18.

PMID:
23777213
26.

Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

Cipriani P, Di Benedetto P, Liakouli V, Del Papa B, Di Padova M, Di Ianni M, Marrelli A, Alesse E, Giacomelli R.

Clin Exp Immunol. 2013 Aug;173(2):195-206. doi: 10.1111/cei.12111.

27.

The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.

Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E.

Biomed Res Int. 2013;2013:187204. doi: 10.1155/2013/187204. Epub 2012 Dec 30. Review.

28.

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E.

BMC Med. 2013 Mar 4;11:59. doi: 10.1186/1741-7015-11-59.

29.

Serum biomarkers identification by mass spectrometry in high-mortality tumors.

Tessitore A, Gaggiano A, Cicciarelli G, Verzella D, Capece D, Fischietti M, Zazzeroni F, Alesse E.

Int J Proteomics. 2013;2013:125858. doi: 10.1155/2013/125858. Epub 2013 Jan 15.

30.

Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.

Cipriani P, Carubbi F, Liakouli V, Marrelli A, Perricone C, Perricone R, Alesse E, Giacomelli R.

Autoimmun Rev. 2013 May;12(7):709-16. doi: 10.1016/j.autrev.2012.10.004. Epub 2012 Nov 24. Review.

PMID:
23183379
31.

Targeting costimulatory molecules to improve antitumor immunity.

Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E.

J Biomed Biotechnol. 2012;2012:926321. doi: 10.1155/2012/926321. Epub 2012 Feb 12. Review.

32.

The tumor suppressor gene KCTD11REN is regulated by Sp1 and methylation and its expression is reduced in tumors.

Mancarelli MM, Zazzeroni F, Ciccocioppo L, Capece D, Po A, Murgo S, Di Camillo R, Rinaldi C, Ferretti E, Gulino A, Alesse E.

Mol Cancer. 2010 Jun 30;9:172. doi: 10.1186/1476-4598-9-172.

33.

The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.

Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegård D, Teti A.

J Cell Biol. 2009 Nov 30;187(5):669-83. doi: 10.1083/jcb.200906014.

34.

Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.

Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A.

Endocr Relat Cancer. 2009 Sep;16(3):1029-43. doi: 10.1677/ERC-09-0094. Epub 2009 Jun 25.

35.

Proapoptotic function of the retinoblastoma tumor suppressor protein.

Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, Lees JA.

Cancer Cell. 2009 Mar 3;15(3):184-94. doi: 10.1016/j.ccr.2009.01.026.

36.

Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation.

Passacquale G, Desideri G, Croce G, Murgo S, Mancarelli MM, Zazzeroni F, Alesse E, Ferri C.

J Hypertens. 2008 Apr;26(4):737-46. doi: 10.1097/HJH.0b013e3282f4d1bd.

PMID:
18327084
37.

Differential expression of neurogenins and NeuroD1 in human pituitary tumours.

Fratticci A, Grieco FA, Spilioti C, Giangaspero F, Ventura L, Esposito V, Piccirilli M, Santoro A, Gulino A, Cantore G, Alesse E, Jaffrain-Rea ML.

J Endocrinol. 2007 Sep;194(3):475-84.

PMID:
17761887
38.

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.

Recchia F, Saggio G, Cesta A, Candeloro G, Di Blasio A, Amiconi G, Lombardo M, Nuzzo A, Lalli A, Alesse E, Necozione S, Rea S.

Cancer Immunol Immunother. 2007 May;56(5):699-708. Epub 2006 Sep 6.

PMID:
16955297
39.

Reduction of glutamate levels in HIV-infected subjects treated with acetylcarnitine.

Famularo G, Moretti S, Alesse E, Trinchieri V, Angelucci A, Santini G, Cifone G, De Simone C.

J NeuroAIDS. 1999;2(2):65-73.

PMID:
16873195
40.

Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

Recchia F, Saggio G, Nuzzo A, Biondi E, Di Blasio A, Cesta A, Candeloro G, Alesse E, Rea S.

J Immunother. 2006 Jan-Feb;29(1):87-94.

PMID:
16365604
41.

Age-associated changes in mouse oocytes during postovulatory in vitro culture: possible role for meiotic kinases and survival factor BCL2.

Tatone C, Carbone MC, Gallo R, Delle Monache S, Di Cola M, Alesse E, Amicarelli F.

Biol Reprod. 2006 Feb;74(2):395-402. Epub 2005 Oct 26.

PMID:
16251501
42.

Hedgehog antagonist REN(KCTD11) regulates proliferation and apoptosis of developing granule cell progenitors.

Argenti B, Gallo R, Di Marcotullio L, Ferretti E, Napolitano M, Canterini S, De Smaele E, Greco A, Fiorenza MT, Maroder M, Screpanti I, Alesse E, Gulino A.

J Neurosci. 2005 Sep 7;25(36):8338-46.

43.
44.

Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.

Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Di Bitondo R, Ferretti E, Mainiero F, Bizzarri C, Colotta F, Bertini R.

Biochem Pharmacol. 2005 Feb 1;69(3):385-94. Epub 2004 Dec 9.

PMID:
15652230
45.

Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway.

De Smaele E, Di Marcotullio L, Ferretti E, Screpanti I, Alesse E, Gulino A.

Cell Cycle. 2004 Oct;3(10):1263-6. Epub 2004 Oct 3. Review.

PMID:
15467454
46.

REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma.

Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, Modesti A, Giangaspero F, Screpanti I, Alesse E, Gulino A.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8. Epub 2004 Jul 12.

47.

Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage.

Ianari A, Gallo R, Palma M, Alesse E, Gulino A.

J Biol Chem. 2004 Jul 16;279(29):30830-5. Epub 2004 May 3.

48.

Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1.

Ferretti E, Di Stefano D, Zazzeroni F, Gallo R, Fratticci A, Carfagnini R, Angiulli S, Santoro A, Minniti G, Tamburrano G, Alesse E, Cantore G, Gulino A, Jaffrain-Rea ML.

J Endocrinol Invest. 2003 Oct;26(10):957-65.

PMID:
14759067
49.

Differential regulation of E2F1 apoptotic target genes in response to DNA damage.

Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L, Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, Levrero M.

Nat Cell Biol. 2003 Jun;5(6):552-8.

PMID:
12766778
50.

Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability.

Desideri G, Bravi MC, Tucci M, Croce G, Marinucci MC, Santucci A, Alesse E, Ferri C.

Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1218-23. Epub 2003 May 22.

PMID:
12763763

Supplemental Content

Loading ...
Support Center